Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2017-07-03 Regulatory Filings
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the assignment of a lease from Adaptimmune Therapeutics plc to Immunocore Limited, including details about office space relocation. There is no financial data, earnings information, or detailed report content. The document is not an annual or quarterly report, nor is it a call transcript or governance document. It is a regulatory announcement of a corporate event. Given the nature of the Form 8-K and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories. The document length is under 5,000 characters and it is a standalone announcement, not a report publication announcement. Therefore, the classification is RNS with high confidence.
2017-07-03 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 21, 2017, reporting on the submission of matters to a vote of security holders at the company's Annual General Meeting (AGM). It details the voting results for various resolutions including director re-elections, auditor appointments, and share allotment authorizations. The content focuses on the official results of shareholder votes at the AGM, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full annual report, audit report, or proxy statement, but specifically the voting results from the AGM. Therefore, the appropriate classification is DVA with high confidence.
2017-06-21 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 6, 2017, reporting on a live teleconference and webcast slide presentation discussing updated data from a clinical study. The document references a slide presentation (Exhibit 99.1) attached to the filing. The content focuses on an event and presentation materials rather than a full financial report or earnings release. The document length is 4616 characters, which is relatively short and primarily serves as an announcement of the presentation event and materials. According to the rules, such documents that announce or provide presentation materials without substantive financial data or detailed report content should be classified as Investor Presentation (IP).
2017-06-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 5, 2017. It reports an event categorized under Item 8.01 "Other Events," specifically announcing an oral presentation and a press release about updated clinical data from a study. The document includes a press release as an exhibit and mentions a webcast and teleconference. There are no financial statements or detailed financial data included. The content is primarily an announcement of an event and related press release, not a full financial report or earnings release. Given the nature of the document as a current report announcing an event and press release, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-06-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement (a lease agreement) and an announcement of an upcoming oral presentation and webinar related to clinical trial data. There are no financial statements or detailed financial results presented, nor is this an earnings release or annual/interim report. The document also includes a press release as an exhibit. The nature of the filing is an update on material agreements and other events, typical of an 8-K regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements such as Form 8-K filings that do not fit other categories.
2017-05-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 25, 2017, reporting an event under Item 8.01 'Other Events'. It announces the initiation of a study involving NY-ESO SPEAR T-cells in combination with KEYTRUDA. The document includes a press release as Exhibit 99.1. The text explicitly states that the information is not deemed 'filed' for purposes of Section 18 of the Exchange Act and is incorporated by reference only. The document is short (4016 characters) and primarily serves as an announcement of a corporate event and press release, not a detailed financial report or earnings release. There is no substantive financial data or detailed financial results presented. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2017-05-25 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.